Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Breast Neoplasms 9Carcinoma, Non-Small-Cell Lung 6Carcinoma, Hepatocellular 6Recurrence 5Pancreatic Neoplasms 5Neoplasms 5Stomach Neoplasms 4Solid Tumor 4Melanoma 4Liver Neoplasms 4Advanced Solid Tumors 4Neoplasm Metastasis 3Nasopharyngeal Carcinoma 3Leukemia, Myeloid, Acute 3Biliary Tract Neoplasms 3Advanced Solid Tumor 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Thoracic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Multiple Myeloma 2Lymphoma, Large B-Cell, Diffuse 2Lung Neoplasms 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Urinary Bladder Neoplasms 1Squamous Cell Lung Cancer 1

Interventions

blinatumomab 2Carboplatin 2venetoclax 1treosulfan 1flumatinib 1fludarabine phosphate 1anlotinib 1aflutinib 1Whole-Body Irradiation 1Tyrosine Kinase Inhibitors 1Peripheral Blood Stem Cell Transplantation 1Neoadjuvant Therapy 1Maintenance 1Interferon alpha-2 1Inotuzumab Ozogamicin 1Injections 1Immunotherapy 1Drug Therapy 1Docetaxel 1Decitabine 1Cytarabine 1Cyclophosphamide 1Chemotherapy, Adjuvant 1Carmustine 1Busulfan 1Bortezomib 1Blood Specimen Collection 1Azacitidine 1Anti-Inflammatory Agents, Non-Steroidal 1Aminolevulinic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Neoplasm, Residual × Injections × Clear all
NCT04604691 2022-03-08

Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD)

Seoul National University Hospital

Phase 1 Unknown
20 enrolled
LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡